NCT06066242View on ClinicalTrials.gov

Optimizing Induction Chemotherapy Regimens for ND Elderly AML Patients Who Are Eligible for Intense Chemotherapy

NARecruitingINTERVENTIONAL
Enrollment

90

Participants

Timeline

Start Date

October 1, 2023

Primary Completion Date

October 10, 2025

Study Completion Date

October 10, 2025

Conditions
Acute Myeloid Leukemia
Interventions
OTHER

Different induction chemotherapy regimens

azacitidine combined with venetoclax or chemotherapy with or without venetoclax

Trial Locations (1)

Unknown

RECRUITING

Institute of Hematology & Blood Diseases Hospital, Tianjin

All Listed Sponsors
lead

Institute of Hematology & Blood Diseases Hospital, China

OTHER